AnaCardio

Series-B+
anacardio.com Biotech & Healthcare Solna, Sweden 11-50
Total Funding $90.0M
Latest Round $71.0M Series-B+
Last Announced Sep 30, 2026
Investors 11 Backers
Decision Makers 3 Verified

About AnaCardio

AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Solna, Sweden
Team Size 11-50
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website anacardio.com
Domain Registered Date Apr 19, 2017

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

4 Events
  1. Capital Raise

    Raised $70,968,750 · Series-B+

    anacardio.com

  2. Capital Raise

    Raised $19,000,000 · Venture Round

    fundraisingfox.com

  3. Capital Raise

    Series-A announced

    fundraisingfox.com

  4. Milestone

    Website domain registered

    anacardio.com

Investors & Backers

11
3B Ventures
Flerie Invest
Fredrik Ljungström
Helsinn Healthcare
Industrifonden
Innovestor
LLD Nybohov Invest AB
Novo Holdings
Pureos Bioventures
Sound Bioventures
The Ljungstrom Family Office

Funding History

3 Rounds
Series-B+ · Sep 30, 2026
$70,968,750 anacardio.com
Venture Round · Jan 9, 2025
Series-A · Sep 7, 2022

Founders & Leadership

2

Patrik Stromberg

CEO

Work email & phone locked Unlock →

Philipp Mathieu

Chief Financial Officer

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts